FDA Approves ZYN Nicotine Pouches

Nicotine pouches get FDA approval, with some calling them Gen Z's favorite weight loss hack
Little pouches of nicotine sold by the brand ZYN were given the green light for marketing this week through the U.S. Food and Drug Administration’s premarket tobacco product application (PMTA) pathway.
Zyn nicotine pouches, dubbed 'Gen Z’s weight loss secret,' secure FDA approval
Zyn gains cult status among Gen Z, praised for boosting workouts, alertness, and dubbed O-Zyn-pic for weight loss.
FDA Approves Marketing of Nicotine Pouches
Following an extensive scientific review, the U.S. Food and Drug Administration has authorized the marketing of 20 ZYN nicotine pouch products. Nicotine pouches -- small synthetic fiber pouches containing nicotine -- are designed to be placed between a person's gum and lip.
FDA OKs sales of Zyn nicotine pouches, citing health benefits for adult smokers
FDA officials say that Zyn contains fewer harmful ingredients than cigarettes and other types of chewing tobacco, which are linked with cancer and other diseases.
FDA will allow Zyn nicotine pouches to stay on the market
Zyn products will be allowed to stay on the market after federal health officials said Thursday that the popular nicotine pouches can help adult smokers cut back or switch completely.
FDA approves sales and marketing for Zyn nicotine pouches
Marketing for the popular nicotine pouch product, Zyn, has been approved by the U.S. Food and Drug Administration to help smokers quit cigarettes and other tobacco products.
FDA Approves ZYN Nicotine Pouches As Safer Alternative For Adult Tobacco Users
ZYN pouches contain no tobacco, only nicotine, offering a potentially less harmful option for tobacco users, with lower levels of cancer-causing constituents than traditional tobacco products.
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
devdiscourse1d
Hidden Dangers of Compounded Weight-Loss Drugs
A recent study reveals many websites selling compounded versions of weight-loss drugs do not inform users of risks, often ...
Eli Lilly's weight loss pill could get federal approval by early next year
Eli Lilly & Co. ( LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026.
Mounjaro vs. Ozempic: Which One Is Best for Me to Try for Weight Loss in 2025?
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
FOX News on MSN13d
Ozempic ‘microdosing’ is the new weight-loss trend: Should you try it?
This practice is not approved by the U.S. Food and Drug Administration (FDA). "Health care clinicians do not typically ...
BioSpace10d
FDA Proposes Setting Bar for Weight-Loss Therapies as Obesity Space Heats Up
In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...
HealthDay on MSN10d
Some GLP-1s Achieve More Weight Loss Than Others: Study
Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...
devdiscourse1d
Health Headlines: Novartis Win, Weight Loss Boosts, and More
Global health highlights include a court pausing a generic version of a heart drug, Novo Nordisk's weight loss trial success, ...
BioSpace1d
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...